<DOC>
	<DOCNO>NCT00546715</DOCNO>
	<brief_summary>The primary purpose study evaluate safety profile tolerability single oral dos daclatasvir subject chronic hepatitis C infection</brief_summary>
	<brief_title>A Single Ascending Dose Study Daclatasvir ( BMS-790052 ) Hepatitis C Virus Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Key Chronically infect hepatitis C virus genotype 1 Treatment naive treatment nonresponders treatment intolerant ; coinfected HIV hepatitis B virus Hepatitis C virus RNA viral load ≥ 10*5* IU/mL BMI 18 35 kg/m² Key Any significant acute chronic medical illness stable control medication consistent hepatitis C virus infection Major surgery within 4 week study drug administration gastrointestinal surgery could impact absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>